Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche.
Journal
Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004
Informations de publication
Date de publication:
13 Feb 2020
13 Feb 2020
Historique:
received:
14
10
2019
accepted:
30
01
2020
revised:
20
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
The ability of breast cancer cells to interconvert between epithelial and mesenchymal states contributes to their metastatic potential. As opposed to cell autonomous effects, the impact of epithelial-mesenchymal plasticity (EMP) on primary and metastatic tumor microenvironments remains poorly characterized. Herein we utilize global gene expression analyses to characterize a metastatic model of EMP as compared to their non-metastatic counterparts. Using this approach, we demonstrate that upregulation of the extracellular matrix crosslinking enzyme tissue transglutaminase-2 (TG2) is part of a novel gene signature that only emerges in metastatic cells that have undergone induction and reversion of epithelial-mesenchymal transition (EMT). Consistent with our model system, patient survival is diminished when primary tumors demonstrate enhanced levels of TG2 in conjunction with its substrate, fibronectin. Targeted depletion of TG2 inhibits metastasis, while overexpression of TG2 is sufficient to enhance this process. In addition to being present within cells, we demonstrate a robust increase in the amount of TG2 and crosslinked fibronectin present within extracellular vesicle (EV) fractions derived from metastatic breast cancer cells. Confocal microscopy of these EVs suggests that FN undergoes fibrillogenesis on their surface via a TG2 and Tensin1-dependent process. Upon in vivo administration, the ability of tumor-derived EVs to induce metastatic niche formation and enhance subsequent pulmonary tumor growth requires the presence and activity of TG2. Finally, we develop a novel 3D model of the metastatic niche to demonstrate that conditioning of pulmonary fibroblasts via pretreatment with tumor-derived EVs promotes subsequent growth of breast cancer cells in a TG2-dependent fashion. Overall, our studies illustrate a novel mechanism through which EMP contributes to metastatic niche development and distant metastasis via tumor-derived EVs containing aberrant levels of TG2 and fibrillar FN.
Identifiants
pubmed: 32054828
doi: 10.1038/s41389-020-0204-5
pii: 10.1038/s41389-020-0204-5
pmc: PMC7018754
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA232589
Organisme : NCI NIH HHS
ID : R01 CA232589
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA198929
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207751
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ID : R21AA026675
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA207751
Organisme : NCI NIH HHS
ID : P30 CA023168
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R00CA198929
Organisme : American Cancer Society (American Cancer Society, Inc.)
ID : RSG-CSM130259
Organisme : NIAAA NIH HHS
ID : R21 AA026675
Pays : United States
Références
American Cancer Society. American Cancer Society, Cancer Treatment and Survivorship Facts and Figures. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf (2016).
Chitty, J. L. et al. Recent advances in understanding the complexities of metastasis. F1000Research https://doi.org/10.12688/f1000research.15064.2 (2018).
doi: 10.12688/f1000research.15064.2
Shinde, A. et al. Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer. Cancer Res. 79, 1831–1843 (2019).
doi: 10.1158/0008-5472.CAN-18-2636
Katsuno, Y. et al. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci. Signal. 12, eaau8544 (2019).
doi: 10.1126/scisignal.aau8544
Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).
doi: 10.1038/onc.2010.215
Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982–3989 (2017).
doi: 10.1158/0008-5472.CAN-16-3292
Wendt, M. K., Taylor, M. A., Schiemann, B. J. & Schiemann, W. P. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol. Biol. Cell 22, 2423–2435 (2011).
doi: 10.1091/mbc.e11-04-0306
Neelakantan, D. et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat. Commun. 8, 15773 (2017).
doi: 10.1038/ncomms15773
Shinde, A. et al. Autocrine fibronectin inhibits breast cancer metastasis. Mol. Cancer Res. 16, 1579–1589 (2018).
doi: 10.1158/1541-7786.MCR-18-0151
Schmidt, J. M. et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 10, 131–139 (2015).
doi: 10.1016/j.celrep.2014.12.032
Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706–5716 (2010).
doi: 10.1158/0008-5472.CAN-09-2356
Katt, W. P., Antonyak, M. A. & Cerione, R. A. The diamond anniversary of tissue transglutaminase: a protein of many talents. Drug Discov. Today 23, 575–591 (2018).
doi: 10.1016/j.drudis.2018.01.037
Philp, C. J. et al. Extracellular matrix cross-linking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 594–603 (2018).
doi: 10.1165/rcmb.2016-0379OC
Wang, X. et al. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway. Oncotarget 7, 7066–7079. (2016).
pubmed: 26771235
pmcid: 4872769
Diaz-Hidalgo, L. et al. Transglutaminase type 2-dependent selective recruitment of proteins into exosomes under stressful cellular conditions. Biochim. Biophys. Acta 1863, 2084–2092 (2016).
doi: 10.1016/j.bbamcr.2016.05.005
Purushothaman, A. et al. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J. Biol. Chem. 291, 1652–1663 (2016).
doi: 10.1074/jbc.M115.686295
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).
doi: 10.1038/nature15756
Györffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725–731 (2010).
doi: 10.1007/s10549-009-0674-9
Balanis, N. et al. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J. Biol. Chem. 288, 17954–17967 (2013).
doi: 10.1074/jbc.M113.475277
Brown, W. S., Tan, L., Smith, A., Gray, N. S. & Wendt, M. K. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol. Cancer Ther. 15, 2096–2106 (2016).
doi: 10.1158/1535-7163.MCT-16-0136
Wendt, M. K., Taylor, M. A., Schiemann, B. J., Sossey-Alaoui, K. & Schiemann, W. P. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res. 16, R24 (2014).
Oh, K. et al. Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 13, R96 (2011).
Moon, P.-G. et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget 7, 40189–40199 (2016).
pubmed: 27250024
pmcid: 5130002
Chen, I.-H. et al. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc. Natl Acad. Sci. USA 114, 3175–3180 (2017).
doi: 10.1073/pnas.1618088114
Pankov, R. et al. Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J. Cell Biol. 148, 1075–1090 (2000).
doi: 10.1083/jcb.148.5.1075
Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep. 14, 2281–2288 (2016).
doi: 10.1016/j.celrep.2016.02.034
Park, M. K. et al. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation. Eur. J. Cancer 49, 1692–1705 (2013).
doi: 10.1016/j.ejca.2012.11.036
Brown, W. S., Akhand, S. S., Wendt, M. K., Brown, W. S. & Wendt, M. K. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. Oncotarget 7, 83424–83436 (2016).
pubmed: 27825137
pmcid: 5347779
Gundemir, S., Colak, G., Tucholski, J. & Johnson, G. V. W. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys. Acta 1823, 406–419 (2012).
doi: 10.1016/j.bbamcr.2011.09.012
Whiteside, T. L. Tumor-derived exosomes and their role in cancer progression. Adv. Clin. Chem. 74, 103–141 (2016).
doi: 10.1016/bs.acc.2015.12.005
Antonyak, M. A. et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc. Natl Acad. Sci. USA 108, 4852–4857 (2011).
doi: 10.1073/pnas.1017667108
Lodge, M., da, S., Nahas, M. E. & Johnson, T. S. Urinary transglutaminase 2 as a potential biomarker of chronic kidney disease detection and progression. Lancet 381, S33 (2013).
doi: 10.1016/S0140-6736(13)60473-0
Tarantino, U., Ferlosio, A., Arcuri, G., Spagnoli, L. G. & Orlandi, A. Transglutaminase 2 as a biomarker of osteoarthritis: an update. Amino Acids 44, 199–207 (2013).
doi: 10.1007/s00726-011-1181-y
Wendt, M. K. & Schiemann, W. P. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res. 11, R68 (2009).
doi: 10.1186/bcr2360
McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012).
doi: 10.1093/nar/gks042
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
doi: 10.1093/bioinformatics/btw313
Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).
doi: 10.1038/nature22341
Greening, D. W., Xu, R., Ji, H., Tauro, B. J. & Simpson, R. J. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. Methods Mol. Biol. 1295, 179–209 (2015).
doi: 10.1007/978-1-4939-2550-6_15
Jung, M. K. & Mun, J. Y. Sample preparation and imaging of exosomes by transmission electron microscopy. J. Vis. Exp. 56482 (2018).